UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000010429 |
|---|---|
| Receipt number | R000012125 |
| Scientific Title | An exploratory study to evaluate biomarkers as predictive and /or prognostic factors of benefit from randomized phase ll study of mFOLFOX6+bevacizumab or mFOLFOX6+cetuximab in liver only metastasis from KRAS wild type colorectal cancer |
| Date of disclosure of the study information | 2013/04/05 |
| Last modified on | 2019/10/10 10:35:23 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
An exploratory study to evaluate biomarkers as predictive and /or prognostic factors of benefit from randomized phase ll study of mFOLFOX6+bevacizumab or mFOLFOX6+cetuximab in liver only metastasis from KRAS wild type colorectal cancer
Acronym
Exploratory study in achievement of improved survival by molecular targeted chemotherapy and liver resection for not optimally resectable colorectal liver metastases
Scientific Title
An exploratory study to evaluate biomarkers as predictive and /or prognostic factors of benefit from randomized phase ll study of mFOLFOX6+bevacizumab or mFOLFOX6+cetuximab in liver only metastasis from KRAS wild type colorectal cancer
Scientific Title:Acronym
Exploratory study in achievement of improved survival by molecular targeted chemotherapy and liver resection for not optimally resectable colorectal liver metastases
Region
| Japan |
Condition
Condition
liver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol 2.0 edition) colorectal cancer
Classification by specialty
| Medicine in general | Gastroenterology | Hepato-biliary-pancreatic medicine |
| Surgery in general | Gastrointestinal surgery | Hepato-biliary-pancreatic surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
The correlation between the values of angiogenesis-related growth factors in plasma and efficacy, and biomarkers relevant as prognostic factors or predictive factors for sensitivity or resistance to treatment will be examined exploratively.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Developmental phase
Not applicable
Assessment
Primary outcomes
To evaluate the values of angiogenesis-related growth factors in plasma with Progression-free survival (PFS); centrally assessed
Key secondary outcomes
1) To evaluate the correlation of values of angiogenesis-related growth factors in plasma with efficacy and adverse events
- Response rate (RR)
- Tumor shrinkage rate at week 8
- Liver resection rate
- R0 liver resection rate (patholigically confirmed)
- Progression-free survial (PFS); CT/MRI image assessed by the attending physician
- Time to treatment-failure (TTF)
- Overall survival (OS)
- Incidence of adverse events (drag-related, surgery-related)
- Exploratory endpoints
- Primary endpoint and secondary endpoints in the RAS wild-type subpopulation
2) Exploratory analysis of the relevance of tumor size and expression level of angiogenesis-related growth factors in plasma
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
YES
Dynamic allocation
YES
Institution consideration
Institution is not considered as adjustment factor.
Blocking
NO
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
mFOLFOX6 + bevacizumab
Interventions/Control_2
mFOLFOX6 + cetuximab
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | months-old | <= |
Age-upper limit
| 80 | months-old | >= |
Gender
Male and Female
Key inclusion criteria
Patients who registered the ATOM trial and signed informed consent prior to initiation of any trial-specific procedure and treatment.
Key exclusion criteria
None
Target sample size
100
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Ichinosuke Hyodo / Yoshihiro Kakeji |
Organization
Graduate School of Comprehensive Human Sciences, Tsukuba University / Kobe University Graduate School of Medicine
Division name
Department of Gastroenterology / Division of Gastrointestinal Surgery, Department of Surgery
Zip code
Address
2-1-1 Amakubo, Tsukuba, 305-8576, Japan / 7-5-2 Kusunoki-cho, Chuo-ku, Kobe-city, 650-0017, Japan
TEL
03-5684-7767
prj-atomdc@eps.co.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | EPS Corporation |
Organization
EPS Corporation
Division name
CRO Company Clinical Information Division
Zip code
Address
6-29 Shinogawamachi, Shinjuku-ku, Tokyo, 162-0814, Japan
TEL
03-5684-7767
Homepage URL
prj-atomdc@eps.co.jp
Sponsor or person
Institute
EPS Corporation
Institute
Department
Personal name
Funding Source
Organization
CHUGAI PHARMACEUTICAL CO., LTD
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
YES
Study ID_1
NCT01834014
Org. issuing International ID_1
ClinicalTrials.gov
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
<北海道>
函館五稜郭病院
北海道大学病院
市立札幌病院
釧路労災病院
<青森>
弘前大学医学部附属病院
<宮城>
石巻赤十字病院
東北大学病院
<秋田>
大曲厚生医療センター
<山形>
公立置賜総合病院
<福島>
いわき市立総合磐城共立病院
<茨城>
日立総合病院
土浦協同病院
茨城県立中央病院
筑波大学附属病院
水戸医療センター
<群馬>
群馬県立がんセンター
<千葉>
帝京大学ちば総合医療センター
千葉県がんセンター
国保旭中央病院
<東京>
東邦大学医療センター大森病院
東京医科歯科大学医学部附属病院
東京女子医科大学
都立駒込病院
<神奈川>
横須賀市立うわまち病院
昭和大学藤が丘病院
横浜市立大学附属病院
昭和大学横浜市北部病院
<新潟>
新潟県立がんセンター新潟病院
<石川>
金沢赤十字病院
石川県立中央病院
<福井>
福井県済生会病院
福井県立病院
福井大学医学部附属病院
<岐阜>
朝日大学歯学部附属村上記念病院
松波総合病院
岐阜大学
<静岡>
聖隷浜松病院
浜松医療センター
<愛知>
名古屋市立大学
愛知県がんセンター中央病院
名古屋医療センター
半田市立半田病院
<三重>
三重大学医学部附属病院
<滋賀>
滋賀県立成人病センター
大津市民病院
<京都>
京都桂病院
京都大学医学部附属病院
<大阪>
大阪医科大学附属病院
済生会中津病院
近畿大学
<兵庫>
佐野病院
神戸医療センター
姫路赤十字病院
兵庫医科大学
神戸市立医療センター中央市民病院
神戸大学
西神戸医療センター
兵庫県立西宮病院
明和病院
<岡山>
岡山大学病院
<広島>
中国中央病院
県立広島病院
広島大学
<山口>
下関医療センター
山口大学医学部附属病院
<徳島>
徳島大学病院
<香川>
香川大学医学部附属病院
<愛媛>
四国がんセンター
松山赤十字病院
<福岡>
久留米大学
飯塚病院
九州中央病院
久留米大学医療センター
済生会福岡総合病院
JCHO九州病院
九州大学
九州医療センター
北九州総合病院
九州がんセンター
製鉄記念八幡病院
<佐賀>
佐賀大学医学部附属病院
<長崎>
佐世保市立総合病院
長崎大学
<熊本>
熊本大学
済生会熊本病院
<大分>
別府医療センター
大分赤十字病院
<鹿児島>
鹿児島大学
<沖縄>
中頭病院
那覇市立病院
琉球大学医学部附属病院
Other administrative information
Date of disclosure of the study information
| 2013 | Year | 04 | Month | 05 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2013 | Year | 03 | Month | 05 | Day |
Date of IRB
| 2013 | Year | 02 | Month | 28 | Day |
Anticipated trial start date
| 2013 | Year | 05 | Month | 07 | Day |
Last follow-up date
| 2017 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
| 2017 | Year | 04 | Month | 30 | Day |
Date trial data considered complete
| 2017 | Year | 06 | Month | 30 | Day |
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2013 | Year | 04 | Month | 05 | Day |
Last modified on
| 2019 | Year | 10 | Month | 10 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012125
